Terray Therapeutics

Terray Therapeutics focuses on the discovery and development of small-molecule drugs using its proprietary computational platform TNova. It leverages AI to synthesize, screen, and analyze chemical compounds as well as map biochemical interactions with diseases to identify the highest potential molecules for drug development. The platform’s dataset includes more than 2 billion unique target-ligand binding measurements, which increases by 150 million each month.

The platform uses a closed-loop system, which enables it to reassess potential candidates based on their performances. Terray’s platform can be applied to any disease area; however, as of 2024, the company had been focusing on immunology diseases.

Key customers and partnerships

The company has several key partners for drug discovery, including 1) Bristol Myers Squibb to pursue the discovery and development of novel small-molecule therapeutics ( December 2023 ) and 2) Calico Life Sciences (Google’s anti-aging healthcare company) to develop novel small-molecule therapeutics for age-related diseases, including cancer ( October 2022 ).

Funding and financials

In November 2023 , the company received an undisclosed amount of equity investment from NVIDIA's venture arm, NVentures, for small-molecule drug discovery. New and existing institutional investors, including John Maraganore, the founding CEO of Alnylam Pharmaceuticals, and Bassil Dahiyat, the founder and CEO of Xencor, also contributed to the round. Before this, the company had raised USD 60 million in a Series A funding round led by Madrona Venture Group when it emerged from stealth in February 2022 .